18
Views
15
CrossRef citations to date
0
Altmetric
Original Article

Induction of “In Vitro” Apoptosis by Fludarabine in Freshly Isolated B-Chronic Lymphocytic Leukemia Cells

, , , , , , , & show all
Pages 95-97 | Received 05 Jun 1993, Published online: 01 Jul 2009

References

  • Keating M.J., Kantarjian H., Talpaz M., et al. Flu-darabine: a new agent with major activity against chronic lym-phocytic leukemia. Blood 1989; 74: 19–25
  • Hiddemann W., Rottmann R., Wormann B., et al. Treatment of advanced chronic lymphocytic leukemia by fludarabine. Results of a clinical phase II study. Ann. Hematol. 1991; 63: 1–4
  • Keating M.J., Kantarjian H., O'Brien S., et al. Flu-darabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia. J. Clin. Oncol. 1991; 9: 44–49
  • Zinzani P.L., Lauria F., Rondelli D., et al. Fludarabine in patients with advanced and/or resistant B-chronic lymphocytic leukemia. Eur. J. Hematol. 1993, (in press)
  • Dow L.W., Bell D.E., Poulakos L., et al. Differences in metabolism and cytotoxicity between 9-β-D-arabino-furanosyladenine and 9-β-D-arabinosyl-2-fluoroadenine in human leukemic lymphoblasts. Cancer Res. 1980; 40: 1405–1410
  • Brockman R.W., Schabel F.M., Jr., Montgomery J.A. Biologic activity of 9-β-D-arabinofuranosyl-2-fluoroadenine, a metabolically stable analog of 9-β-D-arabinofurano-syl-adenine. Biochem. Pharmacol. 1977; 26: 2193–2196
  • Kerr J. F. R., Wyllie A.H., Currie A.R. Apop-tosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br. J. Cancer 1972; 26: 239–257
  • Alley M.C., Scudiero D.A., Monks A., et al. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res. 1988; 48: 589–592
  • Zinzani P.L., Clark J.W., Kouttab N.M., et al. Lymphokine-activated killer (LAK) activity using XTT-micro-culture tetrazolium assay against the melanoma MELTANG cell line. Immunity to Cancer. SBT, Williamsburg. November 16–19, 1989; 14, (abstract N. 36)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.